Regarding the association between the categories of CDX2 expression and the conventional biomarkers, such as the mutational status of the KRAS gene and the status of the MMR/MSI system, the statistical analysis faced limitations due to the irregular assessment of these markers across all stages of colon cancer. The gene discussed is CDX2; the disease is malignant colon neoplasm.